{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:15:24Z","timestamp":1781104524140,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceutical Company Limited, Tokyo, Japan"},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.atherosclerosis.2018.03.023","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T11:20:41Z","timestamp":1521372041000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan"],"prefix":"10.1016","volume":"272","author":[{"given":"Mayumi","family":"Wake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Guelfucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinzo","family":"Hiroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamio","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.5551\/jat.19166","article-title":"Treatment B) Drug Therapy. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan\u00a0\u2212 2012 version","volume":"20","author":"Teramoto","year":"2013","journal-title":"J.\u00a0Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2125.2005.02569.x","article-title":"Initial phase of chronic medication use; patients' reasons for discontinuation","volume":"61","author":"Hugtenburg","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1291\/hypres.30.921","article-title":"Awareness and treatment of hypertension and hypercholesterolemia in Japanese workers: the high-risk and population strategy for occupational health promotion (HIPOP-OHP) study","volume":"30","author":"Tanaka","year":"2007","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5551\/jat.36004","article-title":"Lipid management in a Japanese community. Attainment rate of target set by the Japan Atherosclerosis Society guidelines for the prevention of atherosclerotic cardiovascular diseases 2012","volume":"24","author":"Tada","year":"2017","journal-title":"J.\u00a0Atherosclerosis Thromb."},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2018.03.023_bib7","first-page":"A77","article-title":"Statin adherence and persistence among Japanese patients with high risk vascular disease: a Japan claims database analysis","volume":"6","author":"Zhao","year":"2013","journal-title":"Cardiovascular Quality and Outcomes"},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.atherosclerosis.2016.07.001","article-title":"Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: an analysis of more than 33,000 high cardiovascular risk patients in Japan","volume":"251","author":"Teramoto","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.5551\/jat.15867","volume":"20","author":"Teramoto","year":"2013","journal-title":"J.\u00a0Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib11","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1253\/circj.CJ-08-0095","article-title":"The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia","volume":"72","author":"Ishikawa","year":"2008","journal-title":"Circ. J."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/HYPERTENSIONAHA.108.120584","article-title":"Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA) study","volume":"53","author":"Kushiro","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.5551\/jat.4176","article-title":"MEGA Study Group, Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese","volume":"17","author":"Teramoto","year":"2010","journal-title":"J.\u00a0Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/11595620-000000000-00000","article-title":"Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study)","volume":"28","author":"Nakaya","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1074248411421777","article-title":"The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study","volume":"17","author":"Matsushima","year":"2012","journal-title":"J.\u00a0Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5551\/jat1994.8.33","article-title":"A\u00a0comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE)","volume":"8","author":"Ito","year":"2001","journal-title":"J.\u00a0Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib17","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1253\/circj.66.1087","article-title":"Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia","volume":"66","author":"Matsuzaki","year":"2002","journal-title":"Circ. J."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib18","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1253\/circj.66.1096","volume":"66","author":"Mabuchi","year":"2002","journal-title":"Circ. J."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib19","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/j.1532-5415.2004.52552.x","article-title":"Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan lipid intervention trial","volume":"52","author":"Horiuchi","year":"2004","journal-title":"J.\u00a0Am. Geriatr. Soc."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1253\/circj.69.1016","article-title":"Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT)","volume":"69","author":"Nakaya","year":"2005","journal-title":"Circ. J."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1291\/hypres.28.879","article-title":"The risk of cardiovascular events in Japanese hypertensive patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT) Study, a large-scale observational cohort study","volume":"28","author":"Shimamoto","year":"2005","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib22","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1253\/circj.72.1218","volume":"72","author":"Itakura","year":"2008","journal-title":"Circ. J."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.03.023_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.5551\/jat.2782","article-title":"Obesity as a risk factor for coronary events in Japanese patients with hypercholesterolemia on low-dose simvastatin therapy","volume":"17","author":"Saito","year":"2010","journal-title":"J.\u00a0Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jjcc.2010.09.003","article-title":"Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: efficacy and incidence of cardiac and other events in elderly patients (>\/= 65 years old)","volume":"57","author":"Itakura","year":"2011","journal-title":"J.\u00a0Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erc.11.47","article-title":"Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis","volume":"9","author":"Yokote","year":"2011","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib26","first-page":"388","article-title":"Adherence with statins over 8 years in a usual care setting","volume":"14","author":"Vinker","year":"2008","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib27","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","article-title":"Predictors of nonadherence to statins: a systematic review and meta-analysis","volume":"44","author":"Mann","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib28","unstructured":"[No authors listed], Compliance and adverse event withdrawal: their impact on the west of scotland coronary prevention study. Eur. Heart J.. 18 (1997) 1718\u22121724."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1253\/circj.CJ-09-0746","article-title":"Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia","volume":"74","author":"Origasa","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/03007995.2017.1281109","article-title":"A\u00a0systematic review to assess adherence and persistence with statins","volume":"33","author":"Deshpande","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.023_bib32","first-page":"1677","article-title":"Effects of use of the amlodipine and atorvastatin combination tablet on medication adherence and the control of blood pressure and lipid values","volume":"33","author":"Hano","year":"2012","journal-title":"Ther. Res."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018301485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018301485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T03:01:42Z","timestamp":1534993302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018301485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":32,"alternative-id":["S0021915018301485"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.03.023","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}